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There are many ongoing controversies surrounding vesicoureteral reﬂux (VUR). These include variable aspects of this common
congenital anomaly. Lack of evidence-based recommendations has prolonged the debate. Systematic reviews (SRs) and meta-
analysis (MA) are considered high-level evidence. The purpose of this review article is to summarize and critically appraise the
available SR/MA pertaining to VUR. We also discuss the strength and pitfalls of SR/MA in general. A thorough literature search
identiﬁed9SRs/MAsrelevanttoVUR.Bothauthorscriticallyreviewedthesearticlesforcontentsandmethodologicalissues.There
are many concerns about the quality of the studies included in these SRs. Clinical heterogeneity stemming from diﬀerent patient
selection criteria, interventions, and outcome deﬁnitions is a major issue. In spite of major advances in understanding diﬀerent
aspects of VUR in the last few decades, there is a paucity of randomized controlled trials in this ﬁeld.
Copyright © 2008 K. Afshar and A. E. MacNeily. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Vesicoureteral reﬂux (VUR) is one of the most controversial
topics in pediatric urology. The debate entails several aspects
of VUR, such as clinical signiﬁcance, diagnosis, treatment
options and outcomes. The advent of endoscopic treatment
of VUR has added to the complexity of this debate.
In an era of evidence-based medicine, there is a constant
drive to use best available evidence in every day practice.
Although systematic review (SR) and meta-analysis (MA)
are well-established methods in generating evidence-based
statements, they are not ﬂawless. Speciﬁc steps should be
taken to perform SRs, and clinical or statistical judgment
calls are required of the authors. In addition, the quality of
theavailablestudieshasadirectimpactonthequalityofSRs.
2. METHODS
In this review article, we ﬁrst brieﬂy explain the steps of a
well-performed SR/MA [1] and then apply them to the topic
of VUR. We did not intend to perform a systematic review
of the topic but rather summarize and discuss the available
SR/MA. Therefore, although we performed a thorough lit-
erature search, we did not use a conventional SR protocol.
We included all the available SR/MA discussing any aspect
of VUR (screening, diagnosis, or treatment). Both authors
reviewed and critically appraised all articles.
Whatisasystematicreview(SR)andmeta-analysis(MA)?
SR is a method for secondary data analysis. In these types of
studies, the authors attempt to identify all of the completed
studies in relation to a speciﬁc research question in a
systematic predeﬁned manner. Then by using statistical
methods, these results are combined to answer the research
question based on all eligible studies. The actual statistical
component of a systematic review is referred to as the MA.
StepsinSR/MA
(1) The research question: the cornerstone of an SR/MA
must be a clear and speciﬁc question(s).
(2) Deﬁnition of inclusion and exclusion criteria:f o r
example the authors may only include randomized









population(s), and outcomes of interest should all
be clearly stated. At least two authors should assess
studies eligibility.
(3) Unbiased identiﬁcation of all completed studies:i ti so f
paramount importance that a reproducible protocol
be deﬁned for the identiﬁcation of studies. This
includes a search of all available databases, a hand
search of references and conference proceedings,
and contact of experts in the ﬁeld of interest. One
common pitfall is to limit the search to few words
or a single database such as MEDLINE. A medical
librarian is an invaluable resource in developing
eﬀective search strategies.
(4) Collection of data from each study: standardized data
collection forms are available and should be used
to facilitate the subsequent analysis. Quality of the
included studies is also assessed and recorded. There
are multiple validated tools for this purpose. It is
recommended that at least two authors collect the
data independently.
(5) Clear presentation of ﬁndings: a summary of the
results of literature search and reasons for exclusion
ofstudiesshouldbeprovided.Qualityoftheincluded
studies should be discussed. The quality of reporting
of meta-analyses (QUOROM) statement provides
valuable guidelines for the authors [2].
(6) The process of meta-analysis
(a) Summary eﬀect estimate and conﬁdence inter-
val. This is an average eﬀect size, weighted
by the size of the study. For example if the
meta-analysis is combining the eﬀect of a
procedure versus antibiotics in preventing UTI,
the ﬁnal eﬀect size is presented by a relative
risk (RR). This is a weighted average size
and describes a ratio between the incidence
of UTI in two groups. The 95% conﬁdence
intervaldeterminesthestatisticalsigniﬁcanceof
the summary eﬀect measure. If the interval is
including 1 (RR = 1: equal incidence of UTI in
the 2 groups), the ﬁndings are not statistically
signiﬁcant (P>. 05).
(b) Heterogeneity: if the studies are too heteroge-
neous in terms of design, population, interven-
tionoroutcomes,theyshouldnotbecombined.
The authors must decide about this important
issue based on their expertise and judgment.
Combining these dissimilar studies will lead to
clinical heterogeneity. There are statistical tests
for assessing heterogeneity. If the P value of
these tests is over 0.1, heterogeneity is unlikely,
and combining the ﬁndings from the studies
is reasonable. The P value of 0.1 is usually
used instead of 0.05, to be less conservative in
detecting heterogeneity. Forrest plot is a well-
accepted graphic method to summarize the
ﬁnding of M/A. It shows the eﬀect size for each
study and the whole analysis, along with the
95% CI. The results of the tests of heterogeneity
and the sample size are usually presented as
well.
(c) Assessmentofpublicationbias:itisnotunusual
that small and negative studies are not pub-
lished. An easy way to detect this bias is to
generate a funnel plot. This is a scatter plot with
the measure of eﬀect and sample size on the X
and Y axis, respectively. If publication bias is
present the portion of the graph representing
negative studies will be lacking.
(d) Subgroup and sensitivity analyses: in subgroup
analysis the data from some subsets of studies
are analyzed together (e.g., studies only looking
atcertainagegroupsarecombined).Insensitiv-
ity analysis, the MA is done with and without
certain studies to estimate their overall eﬀects
on the results.
The major shortcoming of an SR is that its quality is totally
dependent on the quality of the included studies, the so-
called “garbage in-garbage out” eﬀect. This is a major issue
when observational studies are analyzed. Confounders and
bias are the two main pitfalls of these types of studies.
Confounders are factors associated with both exposure and
outcome that are not in the path of causation (see Figure 1).
For example, if a cohort study determines coﬀee drinking is
associated with bladder cancer, one could consider cigarette
smoking as a confounder. Smokers may drink more coﬀee
(association with exposure). In addition, smoking is a
known risk factor for bladder cancer (association with the
outcome). So any association between consuming coﬀee and
bladder cancer could be entirely due to the confounding
eﬀect of smoking. Bias is a systematic error in selection
of cases, measurement of outcome, or analysis of the data.
There are statistical ways to minimize confounding and
bias but the most eﬀective method is to randomize the
participants. Therefore, the quality of individual studies
should be assessed carefully and taken into account when
interpreting the overall results of an SR/MA.K. Afshar and A. E. MacNeily 3
3. RESULTS
Systematicreviewsandmeta-analysisforVUR:
A thorough search of available literature yields 9 SR/MA
pertaining to VUR. In the following paragraphs, we critically
appraise the ﬁndings of each paper.
Shanon and Feldman published a review article in 1990
evaluating the methodology of studies on diﬀerent aspects
of VUR [3]. The article by no means fulﬁlls the criteria of
a modern SR due the lack of a reproducible protocol. They
identiﬁed four subsets of article addressing the following
facets of VUR: diagnosis, treatment, association with hyper-
tension, and end stage renal disease. They concluded that
VCUG is the gold standard for diagnosis of VUR. The 4 then
available articles about treatment did not show any advan-
tage for surgery compared to medical treatment in terms
of preventing UTIs or renal scarring. The authors also con-
cluded that although there is a possible association between
VUR and hypertension or end stage renal disease, because of
the low quality of the literature, it could not be estimated
quantitatively. Although the conclusions of this review are
of limited value today, this publication is of importance
since it was the ﬁrst attempt to critically appraise the VUR
literature.
In an SR/MA, Gordon et al. reviewed the literature to
answer the question: “Does the presence of VUR predict
renal damage in children admitted to hospital with urinary
tract infection (UTI)?” [4]. The authors identiﬁed 12 studies
after screening 838 publications which were extracted from 3
major electronic databases. Screened studies were excluded
if more than 10% of data was missing or if they dealt
with outpatients. Test of homogeneity revealed signiﬁcant
heterogeneity among the included studies. This is partly
related to diﬀerent patient populations and study protocols.
Subgroup analysis was not performed. The authors con-
cluded that the presence of VUR is a weak predictor of
renal damage, since a positive voiding cysto-urethrogram
(VCUG) only increased the chance of a positive DMSA renal
scan by 20% and a negative VCUG reduced this chance
by 8%.
Although this SR/MA utilized sound methodologies,
there are some important shortcomings. Above all, the
authors do not discuss the type and quality of the studies
included. It is not clear to the reader if these studies
were prospective or retrospective. Retrospective studies are
prone to bias and confounding and generally are less valid.
Exposure and outcome deﬁnitions may not be the same.
For example how was the UTI diagnosed? what constitutes
a positive DMSA scan? All these factors contribute to
the signiﬁcant heterogeneity and make the interpretation
more diﬃcult. In addition, the ﬁndings are not widely
generalizable since this SR only included inpatients in an era
when most UTIs are managed as outpatients.
Wheeler et al. published an SR/MA regarding antibiotics
versus surgery for the treatment of VUR [5]. The authors
o n l yi n c l u d e dr a n d o m i z e dc o n t r o l l e dt r i a l s( R C T s )w h i c h
allowed the analysis of 8 studies involving 859 children.
No signiﬁcant diﬀerence was found in terms of renal scars
and recurrence of a febrile UTI between the two groups.
Nevertheless, children treated with surgical reimplantation
had a 60% reduction in the risk of febrile UTI over a 5
year period of follow up. The authors concluded that it
is uncertain whether identiﬁcation and treatment of VUR
confer any clinically important beneﬁt. Although this was a
well-performed study, many clinicians will disagree with the
conclusions. In particular, a 60% reduction in the likelihood
of febrile UTIs would likely be considered an important
clinical achievement.
In an SR/MAon the eﬀect of circumcision for prevention
of UTI, Singh-Grewal and colleagues reviewed 12 studies
including over 400000 boys [6]. This included 1 RCT and
11 observational studies. The overall protective eﬀect of
circumcision was both clinically and statistically signiﬁcant
with an odds ratio of 0.13 (P<. 0001). The eﬀect was
unaltered by study design. They estimated that in a general
population, 111 circumcisions are required to prevent one
UTI,duetoalowincidenceofUTI(1%).However,incertain
subgroups of boys that are prone to UTI (such as those with
VUR),thebeneﬁtofcircumcisionbecomesmoreapparent.If
the risk of recurrent UTI in patients with VUR is estimated
to be between 10 and 30%, the number needed to treat will
decrease to between 4 and 11.
This was a well-performed study without any major
methodological ﬂaws. Nonetheless, the quality of the
included studies was variable. Methods of diagnosis of UTI
were not uniform, follow ups were not similar and in
some instances there was signiﬁcant heterogeneity. Based
on these ﬁndings, circumcision should be considered in the
management of boys with VUR and UTI.
Elder and colleagues performed an MA on the success
rate of endoscopic treatment of VUR [7]. They analyzed 63
publications encompassing 5527 patients and 8101 ureters.
Only 3 studies were RCTs, with the rest being observational.
All together, 5 diﬀerent bulking agents were assessed, with
only 6/63 (10%) of studies involving the use of Deﬂux, the
mostwidelyusedagenttoday.Theyfoundoutthattheoverall
success rate of endoscopic treatment regardless of type agent
used and grade of VUR is almost 75% with one injection.
Thiscanbeimprovedto85%withmultipletreatments.High
grade, neuropathic bladders, and duplicated ureters lowered
the success rate. The reported rate of febrile UTI following
treatment was less than 1% and cystitis occurred in 6%
of cases. The paramount conclusion was that the success
rate of endoscopic treatment approaches that of surgical
reimplantation.
However, this study did not meet the standards for a
well-done systematic review; the authors only interrogated
the MEDLINE database plus a hand search of the references
obtained as the basis for their literature search. An additional
weakness is the possible heterogeneity of the studies in terms
of their design, type of treatment, and length of followup.
The authors did not address this issue by doing a test of
heterogeneity.
Williams and colleagues performed an SR/MA to deter-
mine the eﬃcacy of antibiotic prophylaxis for the prevention
of UTI [8]. They included RCTs, comparing the eﬀectiveness
o fa n t i b i o t i c st oe a c ho t h e ro rt op l a c e b o ,i np r e v e n t i o n4 Advances in Urology
of UTIs in children. They analyzed 8 studies, and as a
subset evaluated the eﬀect of antibiotics in prevention of
UTI in children with VUR. Only 2 studies reported the
outcomes separately for patients with and without VUR.
These studies showed a 54% reduction in subsequent
positive urine cultures. The authors detected signiﬁcant
heterogeneity amongst the 8 included studies. Moreover, the
above outcome is not considered clinically important since
most pediatric urologists would not treat asymptomatic
bacteriuria.
Venhola et al. performed a meta-analysis of the eﬃcacy
of medical versus surgical treatment of reﬂux [9]. They used
recurrence of UTI, renal damage, and renal growth as the
outcomes. They screened 639 studies and included only 5
of them in the ﬁnal analysis. They found that the bulk of
studies in the literature on VUR is retrospective and poorly
designed. Their results and conclusions were very similar to
the SR done by Wheeler 2 years earlier. In summary, they did
not show any evidence of superiority of surgical treatment in
preventing UTI, scars, or abnormal growth. This SR/MA has
several shortcomings. The search strategy was suboptimal.
The authors failed to identify at least another 4 trials that
other authors have reported on. They combined the results
of diﬀerent study design types (RCT and cohort). The latter
shortcoming is critical: the design of a study is so important
that even if diﬀerent types of studies reveal similar results,
combining them may be misleading. Although mentioned
in the article, they failed to emphasize a clinically important
ﬁnding: the advantage of surgery over medical treatment in
reduction in the likelihood of pyelonephritis.
Probably the most thorough SR in the VUR literature
is a recent study by Hodson et al. from the Cochrane
Renal Group [10]. This is an update of their SR on the
treatment of VUR published in 2004. They performed an
extensive and systematic literature review and identiﬁed 11
randomized controlled trials involving 1148 children. The
RCTs included 7 comparing surgical (open or endoscopic)
versus medical treatment, 2 compared prophylaxis antibi-
otics with surveillance and 2 compared diﬀerent endoscopic
methods. Although there were a few methodological issues
with some of the RCTs (e.g., blinding of the outcome
assessors, intention to treat analysis), the overall quality of
the 11 included was acceptable. The authors found that
the risk of any UTI is not diﬀerent between surgically and
medically treated groups. However, surgical correction of
VUR results in a 50% reduction in febrile UTI (RR 0.54,
95% CI 0.32–0.92). With a 5 year incidence of febrile UTI
estimated at 20%, the authors estimated that the number
needed to treat to prevent one event was 9. In other words,
9 reimplantations would be required to prevent one episode
of pyelonephritis over a 5 year period. New or progressive
renal damage had a similar incidence in the two groups. In
two small RCTs (total 143 children) with short followup,
the likelihood of UTI was similar in patient on prophylactic
antibiotics versus no treatment. In RCTs, looking at diﬀerent
types of bulking agents silicone (Macroplastique) and Deﬂux
had similar results in terms of VUR correction rate and
recurrent UTI. In a small study, GAX 35 collagen has been
shown to be inferior to GAX 65 in correcting VUR. The
authors concluded that it is uncertain that surgical treatment
of VUR leads to clinically important beneﬁt.
4. DISCUSSION
VUR has been at the centre of many debates in pediatric
urology for several decades, going through several paradigm
shifts. Up to the late 1970’s and even the early 1980’s, VUR
wasconsideredasigniﬁcantdiseaseandwastreatedprimarily
with a variety of open surgeries. Subsequently, large RCTs
such as the International and Birmingham Reﬂux Studies
[11, 12] cast a shadow of doubt on surgical intervention as
the management of ﬁrst choice. These seminal studies were
based on several assumptions:
(1) VUR is a pathologic ﬁnding;
(2) VUR facilitates UTI;
(3) renalparenchymalinfectionmaycauserenaldamage,
hypertension, and renal insuﬃciency;
(4) correction of reﬂux by surgery, or prevention of
UTI with antibiotic prophylaxis until spontaneous
resolution, prevents these unfavorable outcomes.
This resulted in failure of including another management
strategy in these large studies, namely clinical surveillance.
Nevertheless, a new perspective was generated: VUR can be
managed medically and only selected patients will require
surgery. These initial randomized studies also showed that
surgical treatment reduces the likelihood of febrile UTI.
Some authors would question the importance of this out-
come without demonstrating a concomitant reduction in
renal damage. However, one should not ignore the potential
morbidity and even rare mortality associated with febrile
UTI, especially in young children.
More recent ﬁndings have changed the landscape again.
The fact that up to 50% of radiological renal defects could
be congenital and not a consequence of UTI implies that
VUR may be even less clinically important [13]. Studies have
persistently failed to show a beneﬁcial eﬀect for treatment of
VUR in reducing the risk of renal scarring, even when the
incidence of febrile UTI is decreased.
The eﬃcacy and safety of long-term antibiotics have
also been questioned. A recent RCT by Garin et al. did not
demonstrate any beneﬁt from antibiotic versus surveillance
in reducing febrile UTI in children with low and moderate
grade VUR after one year of followup [14]. In addition long-
term antibiotics may not be as harmless as we once thought
[15, 16].
Another major advance is the introduction of a safe
and eﬀective bulking agent for endoscopic treatment of
VUR, that is, Deﬂux. However, this method has never been
compared to other management strategies in a prospective
manner. Again our assumptions have preceded the evidence
in adopting a treatment strategy.
Management of VUR also inﬂuences other important
clinical decisions, such as when to image children with
febrile UTI or siblings of patients with VUR [17]. Finally,
the cost eﬀectiveness and impact on quality of life for theseK. Afshar and A. E. MacNeily 5
investigations and treatments have not been assessed in
prospective fashion.
We believe pediatric urologists should spearhead eﬀorts
to generate the high-level evidence guiding the management
ofVUR.Thebestwayistocomparealltheavailablestrategies
in a randomized controlled trial. Ideally, all important
outcomes should be evaluated with adequate followup.
This requires recruitment of several hundreds patients,
randomizing them into 3 groups (surveillance, antibiotics,
surgery) and following them for 4-5 years. Only with such
a design will questions about recurrence of UTI and renal
damage ever be answered. In addition eﬀects of potential
confounderssuchassex,gradeofVUR,modeofpresentation
and dysfunctional voiding can be evaluated. This will also
provide an opportunity to compare the cost–beneﬁt of each
strategy.
Another major beneﬁt of this ideal study is a better
clariﬁcation of the magnitude of the clinical importance
of VUR. For example, if surveillance is shown to be an
acceptable long-term management, there is no reason to
diagnose VUR, because it would not change our clinical
approach.Ontheotherhand,ifactivetreatmentisassociated
with a better outcome, one can conclude that VUR is a
clinically signiﬁcant phenomenon that requires diagnosis.
There are many barriers to performing an ideal RCT
in children, especially those involving a surgical arm. Ran-
domization between several divergent modalities is usually
met with low parental acceptance. The requirement for
a large sample size combined with long-term followup
will considerably increase the cost, probably to millions of
dollars. It is very diﬃcult if not impossible to perform this
type of studies in a single centre. Multicentre trials are
inherently more expensive and diﬃcult to run. Ethical issues
may also impede the recruitment [18].
In spite of all the adversities, a few RCTs are underway to
answer the above questions [19].
5. CONCLUSIONS
The quality of available studies regarding VUR is highly
variable and in many cases suboptimal. Recent ﬁndings and
advances in diﬀerent aspects of VUR mandate a new look
into our clinical management of this disorder. Ideally, a large
multicentre randomized controlled trial should be done,
including all available management strategies.
ABBREVIATIONS
95% CI: 95% Conﬁdence interval
DMSA: Dimercaptosuccinic acid
MA: Meta-analysis
QUOROM: Quality of reporting of meta-analysis
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